The Ministry of Health and Welfare in Japan approves NovoSeven® for treatment of haemophilia patients with inhibitors

"This approval marks the completion of the initial registrations for NovoSeven® in all the major markets and is an important milestone for us," says Lars Rebien Sørensen, corporate executive vice president, Novo Nordisk, Health Care.

 

NovoSeven® is a genetically engineered blood clotting protein that plays an important role in the sequence of events that normally leads to the formation of a clot in an injured blood vessel. NovoSeven® is indicated for the treatment of bleeding episodes in haemophilia A and B patients with inhibitors (antibodies) to coagulation factors VIII or IX.

 

The approval will not alter Novo Nordisk's financial expectations for 2000.

 

Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzymes. Headquartered in Denmark, Novo Nordisk employs approximately 15,200 people in 68 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen, London and Zurich. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO". A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place around the turn of the year 2000/2001. For further company information, visit Novo Nordisk on the World Wide Web at www.novo.dk.

 

For further information please contact:

 

Communications & Design

 

Media:
Søren Møller Christensen
Phone: (direct) (+45) 4442 1207

 

Media in North America:
Susan Toth Jackson
Phone: (+1) 212-867-0123

 

Investors:
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048

 

Investors:
Carsten Bøss
Phone: (direct) (+45) 4442 6047

 

Investors in North America:
Peter Lundby Hansen
Phone: (+1) 212-878-9607